Non-muscle invasive bladder cancer: New standards in endoscopic management and adjuvant instillations

Poster Session 49

  • Location:
    Room Madrid, North Hall (Level 1)
  • Chairs:
     M. Babjuk, Prague 5 (CZ)
     M. Brausi, Modena (IT)
     M. Burger, Regensburg (DE)
  • Aims and objectives of this session

    Non-muscle invasive bladder cancer (NMIBC) comprises a heterogeneous group in which tumour number, size, grade and pathological stage (pT) are important prognostic factors related to the risk of recurrence, progression and survival. Transurethral resection of bladder tumour (TURBT) is the reference treatment of NMIBC. The accepted standard for “correct” TURBT is complete macroscopic tumour clearance with specimens of the tumour base and resection border sent separately. A key feature of the pathology report is the presence and/or invasion of lamina propria or muscularis propria, the latter being dependent upon the presence of detrusor muscle (DM) in the TURBT specimens. It is now well established that a “correct” TURBT positively influences recurrence and progression. This session aims to provide an overview of new techniques available to improve the quality of TURBT and the deliverance of adjuvant bladder instillations.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
Active surveillance for non-muscle invasive bladder cancer (NMIBC): Result from bladder cancer Italian active surveillance (BIAS) project

By: Hurle R.1, Lazzeri M.1, Saita A.1, Forni G.1, Buffi N.1, Casale P.1, Lughezzani G.1, Peschechera R.1, Pasini L.1, Zandegiacomo S.1, Benetti A.1, Lista G.1, Maffei D.1, Cardone P.1, Colombo P.2, Guazzoni G.1

Institutes: 1Istituto Clinico Humanitas, Dept. of Urology, Rozzano, Italy, 2Istituto Clinico Humanitas, Dept. of Pathology, Rozzano, Italy

Can the use of narrow-band imaging (NBI) reduce persistent bladder cancer rate during white-light classic trans-urethral resection of tumor (WLcTURBT)? A preliminary single-center experience in a large case series

By: Giulianelli R.2, Falavolti C.1, Gentile B.C.2, Mirabile G.2, Tariciotti P.2, Albanesi L.2, Buscarini M.3

Institutes: 1Villa Betania Hospital, Rome, Italy, 2Villa Claudia Clinic, Dept. of Urology, Rome, Italy, 3University Campus Bio-Medico, Dept. of Urology, Rome, Italy

Monopolar versus bipolar transurethral resection for primary non-muscle invasive bladder cancer

By: Liem E.1, McCormack M.2, Chan E.3, Matsui Y.4, Geavlete P.5, Choi Y.6, De Reijke T.1, Farahat Y.7, Inman B.8, De La Rosette J.1, Naito S.9

Institutes: 1Academic Medical Center, Dept. of Urology, Amsterdam, The Netherlands, 2Centre Hospitalier De L’Universite De Montreal, Dept. of Urology, Montreal, Canada, 3Chinese University of Hong Kong, HKSAR, Dept. of Surgery, Hong Kong, China, 4Kyoto University, Dept. of Urology, Kyoto, Japan, 5Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania, 6Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, 7Sheikh Khalifa General Hospital, Dept. of Urology, Umm Al Quwain, United Arab Emirates, 8Duke University Medical Center, Dept. of Urology, Durham, United States of America, 9Harasanshin Hospital, Dept. of Urology, Fukuoka, Japan

Transurethral en-bloc hydrodissection for non-muscle invasive bladder cancer: Results of a randomized controlled trial

By: Gakis G.1, Karl A.2, Bertz S.3, Burger M.4, Fritsche H-M.4, Hartmann A.3, Jokisch F.2, Kempkensteffen C.5, Miller K.5, Mundhenk J.6, Schneevoigt B-S.2, Schubert T.1, Schwentner C.6, Wullich B.7, Stenzl A.1

Institutes: 1Eberhard-Karls University, Dept. of Urology, Tübingen, Germany, 2Ludwig-Maximillians University, Dept. of Urology, Munich, Germany, 3Friedrich-Alexander University, Dept. of Pathology, Erlangen, Germany, 4Caritas St. Joseph´s Hospital, University of Regensburg, Dept. of Urology, Regensburg, Germany, 5Charite, University Medicine Berlin, Dept. of Urology, Berlin, Germany, 6Diakonie-Klinikum, Dept. of Urology, Stuttgart, Germany, 7Friedrich-Alexander University, Dept. of Urology, Erlangen, Germany

Is restaging transurethral resection (TUR) necessary in patients with non-muscle invasive bladder cancer (NMIBC) and focal lamina propria invasion?

By: Audenet F.1, Retinger C.1, Chien C.2, Benfante N.2, Bochner B.1, Donat M.1, Herr H.1, Dalbagni G.1

Institutes: 1Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 2Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America

Bladder endoscopic dissection of NMIBC procures better specimens for pathology than standard TURBT - the pathologists’ perspective

By: Daniel G.1, Quintyn-Rant M-L.1, Brierre T.2, Roumiguié M.2, Malavaud B.2

Institutes: 1Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, 2Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France

Simultaneous transurethral resection of high grade bladder tumor and benign prostatic hyperplasia (BPH): Oncological safety

By: Sionov B.V., Khunovich D., Benjamin S., Sidi A.A., Tsivian A.

Institutes: E. Wolfson M.C. and The Sackler Faculty of Medicine Tel-Aviv University, Dept. of Urologic Surgery, Holon, Israel

Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I and HIVEC II: An interim analysis of 307 patients

By: Tan W.S.1, Palou J.2, Kelly J.1

Institutes: 1University College Hospitals London, Dept. of Surgery and Interventional Sciences, London, United Kingdom, 2Universitat Autònoma De Barcelona – Fundació Puigvert, Dept. of Urology, Barcelona, Spain

Optimal diagnostic performance of photodynamic diagnosis (PDD) and Storz Professional Image Enhancement System (SPIES) is independent from surgeon experience

By: Soria F., Rorato L.M., Pisano F., Allasia M., Pecoraro A., Filippini C., Zitella A., Gontero P.

Institutes: University of Turin, Città Della Salute E Della Scienza Di Torino, Dept. of Surgical Sciences, Division of Urology, Turin, Italy

Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought

By: Palou J.1, Gontero P.2, Pisano F.2, Joniau S.3, Oderda M.2, Serretta V.4, Larrè S.5, Di Stasi S.6, Van Rhijn B.7, Witjes A.J.8, Grotenhuis A.J.8, Colombo R.9, Briganti A.9, Babjuk M.10, Soukup V.10, Malmstrom P.U.11, Irani J.12, Malats N.13, Baniel J.14, Mano R.14, Cai T.15, Cha E.K16, Ardelt P.17, Varkarakis J.18, Bartoletti R.19, Dalbagni G.20, Shariat S.21, Xylinas E.16, Karnes R.J22, Sylvester R.23

Institutes: 1Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 2A.O. Città Della Salute E Della Scienza, University of Turin, Dept. of Urology, Turin, Italy, 3University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 4Paolo Giaccone General Hospital, Dept. of Urology, Palermo, Italy, 5John Radcliffe Hospital, University of Oxford, Dept of Surgical Science, Oxford, United Kingdom, 6Policlinico Tor Vergata-University of Rome, Dept of Urology, Rome, Italy, 7Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept of Urology, Amsterdam, The Netherlands, 8Radboud University Nijmegen Medical Centre, Dept of Urology, Nijmegen, The Netherlands, 9Universit A Vita-Salute. Ospedale S. Raffaele, Dept of Urology, Milan, Italy, 10Motol Hospital, University of Praha, Dept of Urology, Prague, Czech Republic, 11Cademic Hospital, Uppsala University, Dept of Urology, Uppsala, Sweden, 12Centre Hospitalier Universitaire La Mil Etrie, University of Poitiers, Dept of Urology, Poitiers, France, 13Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, Dept. of Genetics, Madrid, Spain, 14Rabin Medical Centre, Dept. of Urology, Tel Aviv, Israel, 15Santa Chiara Hospital, Dept. of Urology, Trento, Italy, 16Weill Medical College of Cornell University, Dept. of Urology, New York, United States of America, 17Chirurgische Universitats Klini, Dept. of Urology, Freiburg, Germany, 18Ismanoglio Hospital, University of Athens, Dept. of Urology, Athens, Greece, 19University of Florences, Dept. of Experimental and Clinical Medicine, Athens, Greece, 20Memorial Sloan Kettering Cancer Center, New York, Dept. of Urology, New York, United States of America, 21Medical University of Vienna, Dept. of Urology, Vienna, Austria, 22Mayo Clinic, Dept. of Urology, Rochester, United States of America, 23ORTC Headquarters, Formerly Department of Biostatistics,, Brussels, Belgium

Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial

By: Tan W.S.1, Buckley L.2, Devall A.2, Loubière L.2, Pope A.2, Feneley M.3, Cresswell J.4, Issa R.5, Mostafid H.6, Madaan S.7, Bhatt R.8, McGrath J.9, Sangar V.10, Griffiths L.11, Page T.12, Hodgson D.13, Datta S.14, Bilingham L.2, Kelly J.1

Institutes: 1University College London, Division of Surgery and Interventional Science, London, United Kingdom, 2University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom, 3University College London Hospitals, Dept. of Urology, London, United Kingdom, 4James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom, 5St George’s Hospital, Dept. of Urology, London, United Kingdom, 6Basingstoke and North Hampshire Hospital, Dept. of Urology, London, United Kingdom, 7Darent Valley Hospital, Dept. of Urology, Dartford, United Kingdom, 8Queen Elizabeth Hospital, Dept. of Urology, Birmingham, United Kingdom, 9Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, 10Withington Hospital, Dept. of Urology, Manchester, United Kingdom, 11Leicester General Hospital, Dept. of Urology, Leicester, United Kingdom, 12Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, 13Queen Alexandra Hospital, Dept. of Urology, Portsmouth, United Kingdom, 14University Hospital of Wales, Dept. of Urology, Cardiff, United Kingdom

5-year outcomes of RITE thermochemotherapy for BCG unresponsive high risk non muscle invasive bladder cancer

By: Ayres B., Sri D., Perry M., Issa R.

Institutes: St George’s Hospital, Dept. of Urology, London, United Kingdom

Comparison of pain, quality of life, lower urinary tract symptoms and sexual function between flexible and rigid cystoscopy in follow-up male patients with non muscle invasive bladder cancer: A randomized controlled cross section single blind study

By: Üçer O., Temeltaş G., Yüksel M.B., Gümüş B., Müezzinoğlu T.

Institutes: Celal Bayar University, Faculty of Medicine, Dept. of Urology, Manisa, Turkey

Guidelines update
 M. Babjuk, Prague 5 (CZ)